Active Filter(s):
Details:
Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.
Lead Product(s): Bioprinted-based Tissue Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $2,675.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration April 12, 2023